Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A5 | Q9Y345 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6402831 | 0.85 | OPRK1 (0.45) | LMNAKMT2AMEN1OPRK1OPRM1 | |
| SCHEMBL6409473 | 0.84 | NPC1 (0.41) | LMNAOPRK1OPRM1MAPTALDH1A1 | |
| SCHEMBL6403180 | 0.71 | MMP3 (0.42) | LMNAKMT2AMEN1ALDH1A1SMN1; SMN2 | |
| SCHEMBL7258293 | 0.70 | L3MBTL1 (0.44) | KMT2AMEN1ALDH1A1ALOX5NPC1 | |
| SCHEMBL6404630 | 0.70 | L3MBTL1 (0.44) | KMT2AMEN1ALDH1A1ALOX5NPC1 | |
| SCHEMBL6409458 | 0.70 | NPC1 (0.42) | LMNAKMT2AOPRK1SMN1; SMN2NPC1 | |
| SCHEMBL6407163 | 0.70 | CA1 (0.42) | KMT2AMEN1ALDH1A1ALOX5 | |
| SCHEMBL6401370 | 0.69 | L3MBTL1 (0.40) | KMT2AMEN1ALDH1A1ALOX5 | |
| SCHEMBL6408723 | 0.69 | CA1 (0.41) | KMT2AMEN1ALDH1A1ALOX5 | |
| SCHEMBL6407167 | 0.68 | CA1 (0.42) | LMNAKMT2AALDH1A1SMN1; SMN2ALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6900237-B2 | Sulfonamide compounds as protease inhibitors | AXYS PHARMACEUTICALS, INC. (US) | 2005-05-31 | — | — | US | disclosed |
| US-20030158231-A1 | Sulfonamide compounds as protease inhibitors | Celera Corporation | 2003-08-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030158231-A1 | Sulfonamide compounds as protease inhibitors | PRSS1, PRSS3, SPINT2 | SLC6A5 1605/4885LMNA 3804/4885KMT2A 2789/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.